Scientific Education

Education

Dec 2010 – Sept 2015 PhD Tumor Immunotherapy Karolinska Institutet
As a PhD candidate I am focused on pioneering advances in current tumor immunotherapies including active as well as passive immunity. In the context of active immunotherapies; we have described an adjuvant encoded by DNA vaccines to boost antitumor immunity as well as elucidating key mechanisms required for establishing tumor specific CTLs from DNA vaccines. Recently we have identified a novel tumor antigen as a potentially interesting vaccine target for treating melanoma as well as breast carcinoma patients. In the context of passive immunotherapy we have been working on endowing T cells with tumor specificity with chimeric antigen receptors as well as protective enzymes to increase their resistance to tumor induced shutdown.

 

Sept 2008 – June 2010 MSc Biotechnology: Medical Biotechnology Wageningen University
Theoretical and practical courses in molecular virology, immunotechnology, general-medicine, and molecular development, etc. Including a nine month long MSc thesis at the Laboratory of Virology in Wageningen University and a nine month long MSc internship at the Immune and Gene Therapy Laboratory in the Karolinska Institutet.

 

Sept 2003 – June 2008 BSc Biotechnology: Cellular and Molecular Biotechnology Wageningen University

 

Theoretical and practical courses in cell biology I and II, molecular biology, control of cellular processes, gene technology, immunology, genetics, bio-information technology, enzymology, microbiology, organic chemistry, physical chemistry, process technology, etc.

Oral Presentations

Oct 2014 PIVAC-14 Italy  
Vaccination against tumor-associated antigen Cripto-1 elicits a protective immune response to melanoma and breast cancer mouse models
Oct 2013 Gene Vaccination in Cancer Italy  
Modulation of NF-κB activity determines efficacy of tumor-specific CTL responses elicited by DNA vaccines
Dec 2012 20th annual DNA Vaccine 2012 USA  
NF-κB activation mediates tumor-specific CTL responses elicited by DNA vaccines

 

Poster Presentations

Feb 2015 Lorne Cancer Conference Australia  
Oxidative burst produced by the NOX2 complex does not play a role in methylcholanthrene induced sarcoma development
June 2014 Norwegian Cancer Symposium Norway  
T-cells co-transduced with Chimeric Antigen Receptors and Catalase are protected from ROS
May 2014 CIMT Mainz Germany  
Cripto-1 encoding DNA vaccine elicits tumor protective immune response in vivo
April 2014 Cancer vaccine and immunomodulation France  
Cripto-1 encoding DNA vaccine elicits tumor protective immune response in vivo
Oct 2013 CSH Asia Tumor Immunotherapy China  
T-cells co-transduced with Chimeric Antigen Receptors and Catalase are protected from ROS
March 2012 AACR Annual Meeting USA  
T-cells co-transduced with Chimeric Antigen Receptors and Catalase are protected from ROS
Sept 2011 Gene Vaccination in Cancer Italy  
NFκB is essential for the immunogenicity of DNA vaccines